Related Experiment Video
Updated: May 26, 2025
An Experimental Model of Myocardial Infarction for Studying Cardiac Repair and Remodeling in Knockout Mice
Published on: July 14, 2023
Galectin-3: Heart failure biomarker in pediatric heart defects
Daniel Gondko1, Patrycja Dębiec1, Jakub Roman1
1Department and Clinic of Pediatric Cardiology, Medical University of Silesia in Katowice, Katowice, Poland.
Insights
Galectin-3 (Gal-3) shows promise as a biomarker for predicting heart failure (HF) in children with congenital heart defects (CHD). Early detection via Gal-3 could improve pediatric HF diagnosis and management.
Area of Science:
- Biochemistry
- Cardiology
- Pediatrics
Background:
- Congenital heart defects (CHD) are common, with heart failure (HF) symptoms varying significantly in pediatric patients.
- Early detection of HF in pediatric CHD is crucial for timely intervention and improved outcomes.
- Current diagnostic methods may not fully capture the progressive nature of HF in this population.
Purpose of the Study:
- To review the current literature on Galectin-3 (Gal-3) as a biomarker for heart failure in pediatric patients with congenital heart defects.
- To highlight the potential of Gal-3 in improving the diagnosis and management of HF in this vulnerable group.
- To consolidate knowledge on Gal-3's role in myocardial remodeling and its predictive utility.
Main Methods:
- Literature review focusing on studies investigating Galectin-3 levels in pediatric patients with CHD and HF.
- Analysis of Gal-3's role in myocardial remodeling processes relevant to heart failure.
- Synthesis of findings regarding Gal-3's diagnostic and prognostic value.
Main Results:
- Galectin-3 (Gal-3) is implicated in myocardial remodeling, a key factor in heart failure development.
- Elevated Gal-3 levels show potential as an early indicator of HF in pediatric CHD patients.
- Gal-3 may offer prognostic insights into disease progression and patient outcomes.
Conclusions:
- Galectin-3 is a promising biomarker for predicting heart failure in pediatric patients with congenital heart defects.
- Utilizing Gal-3 could lead to earlier diagnosis and more effective management strategies for HF in this population.
- Further research is warranted to fully establish Gal-3's clinical utility in pediatric cardiology.
Abstract:
Galectin-3 (Gal-3), a β-galactoside-binding lectin, has emerged as a potential diagnostic and prognostic biomarker for various diseases, including certain heart and kidney diseases, as well as cancer. Its significance is particularly notable in the context of congenital heart defects (CHD), which are the most prevalent congenital malformations, occurring in 6 to 8 out of every 1000 live births. Symptoms of heart failure (HF) in patients with congenital heart defects can manifest early in life, but in some cases, the disease progresses gradually, leading to a gradual decline in quality of life and the development of various complications. This variability underscores the need for early biomarkers to detect HF development in pediatric patients. Gal-3 plays a key role in myocardial remodeling, making it a promising candidate for advancing the diagnosis and management of HF in CHD patients. It is especially relevant in pediatric care, where early detection and intervention can significantly alter disease progression and patient outcomes. This review aims to consolidate current knowledge on the utility of Gal-3 in predicting HF among pediatric patients with CHD, highlighting its potential in changing the direction of diagnosis and treatment in this vulnerable patient population.
